Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Abstract

Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of pembrolizumab at doses of 2 mg/kg and 10 mg/kg every 3 weeks in patients with ipilimumab-refractory advanced melanoma.Methods In an open-label, international, multicentre expansion cohort of a phase 1 trial, patients (aged ≥18 years) with advanced melanoma whose disease had progressed after at least two ipilimumab doses were randomly assigned with a computer-generated allocation schedule (1:1 final ratio) to intravenous pembrolizumab at 2 mg/kg every 3 weeks or 10 mg/kg every 3 weeks until disease progression, intolerable toxicity, or consent withdrawal. Primary endpoint was overall response rate (ORR) assessed with the Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) by independent central review. Analysis was done on the full-analysis set (all treated patients with measurable disease at baseline). This study is registered with ClinicalTrials.gov, number NCT01295827.Findings 173 patients received pembrolizumab 2 mg/kg (n=89) or 10 mg/kg (n=84). Median follow-up duration was 8 months. ORR was 26% at both doses--21 of 81 patients in the 2 mg/kg group and 20 of 76 in the 10 mg/kg group (difference 0%, 95% CI -14 to 13; p=0·96). Treatment was well tolerated, with similar safety profiles in the 2 mg/kg and 10 mg/kg groups and no drug-related deaths. The most common drug-related adverse events of any grade in the 2 mg/kg and 10 mg/kg groups were fatigue (29 [33%] vs 31 [37%]), pruritus (23 [26%] vs 16 [19%]), and rash (16 [18%] vs 15 [18%]). Grade 3 fatigue, reported in five (3%) patients in the 2 mg/kg pembrolizumab group, was the only drug-related grade 3 to 4 adverse event reported in more than one patient.Interpretation The results suggest that pembrolizumab at a dose of 2 mg/kg or 10 mg/kg every 3 weeks might be an effective treatment in patients for whom there are few effective treatment options.Funding Merck Sharp and Dohme.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60958-2

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. Robert, 2013, Updated clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in advanced melanoma, Pigment Cell Melanoma Res, 26, 993
  2. Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/nejmoa1302369 · DOI · Paper page

Cited by

See all 1,774

Metadata

Authors
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R. W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M. A., Gergich, K., Elassaiss-Schaap, J., Li, X. N., Iannone, R., Ebbinghaus, S. W., Kang, S. P., & Daud, A.
Affiliations
  • Inserm (FR)
  • University of California, Los Angeles (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Dana-Farber Cancer Institute (US)
  • Angeles Clinic and Research Institute (US)
  • The University of Sydney (AU)
  • Moffitt Cancer Center (US)
  • Princess Margaret Cancer Centre (CA)
  • The University of Texas MD Anderson Cancer Center (US)
  • Abramson Cancer Center (US)
  • South Texas Accelerated Research Therapeutics (US)
  • Mayo Clinic (US)
  • University of Pittsburgh (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University of California, San Francisco (US)
Corresponding author
Robert, Caroline
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-09
Volume
384
Issue
9948
Pages
1109-1117
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W1990675339
Cited by
1,774
References
32
Citations by year
2026: 22 · 2025: 46 · 2024: 61 · 2023: 79 · 2022: 100 · 2021: 121 · 2020: 154 · 2019: 152 · 2018: 172 · 2017: 229 · 2016: 275 · 2015: 315 · 2014: 44
FWCI
138.69
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
pembrolizumab, PD-1 inhibitors, advanced melanoma, dose comparison, anti-PD-1, overall response rate, immune checkpoint inhibitors, fatigue, immune-related adverse events, treatment safety, immunotherapy, RECIST response assessment, central review
MeSH terms
Ipilimumab, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Drug Eruptions, Dose-Response Relationship, Drug, Fatigue, Female, Humans, Male, Melanoma, Middle Aged, Pruritus, Skin Neoplasms, Treatment Outcome, Drug Resistance, Neoplasm, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(14)60958-2
The paper
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R. W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M. A., Gergich, K., . . . Daud, A. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. https://doi.org/10.1016/s0140-6736(14)60958-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.